SNS-032 was able to induce the degradation of SIX1 through the inactivation of the EGFR-AKT-USP1 axis, and SNS-032 in combination with sorafenib was found to inhibit tumor growth in a mouse model of HCC [199]. This evidence concerns the gene SIX1 and neoplasm.